PAMELOR (nortriptyline hydrochloride) by ANI Pharmaceuticals is clinical pharmacology the mechanism of mood elevation by tricyclic antidepressants is at present unknown. Approved for depression. First approved in 1977.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
PAMELOR (nortriptyline hydrochloride) is a tricyclic antidepressant oral capsule approved in 1977 for depression treatment. It works by interfering with the transport, release, and storage of catecholamines and inhibits diverse agents including histamine, serotonin, and acetylcholine. The exact mechanism of mood elevation remains unknown.
Product is approaching loss of exclusivity with minimal current spending signal (~$2M), indicating a contracting team focused on generic transition management rather than growth.
CLINICAL PHARMACOLOGY The mechanism of mood elevation by tricyclic antidepressants is at present unknown. Pamelor is not a monoamine oxidase inhibitor. It inhibits the activity of such diverse agents as histamine, 5-hydroxytryptamine, and acetylcholine. It increases the pressor effect of…
Working on PAMELOR offers stable but contracting career opportunities as the product navigates loss of exclusivity. Roles emphasize commercial defense, generic transition planning, and maintaining market share rather than growth innovation.
Worked on PAMELOR at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.